GeneDx Holdings Corp.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ARK Invest, led by Cathie Wood, sold shares in multiple crypto-linked holdings, including ARKB, COIN, CRCL, and BMNR. The firm trimmed over 1.5% of its Bitcoin ETF (ARKB) positions. Bitcoin's price fell below $77,000, and retail sentiment remained bearish. Other tech stocks like AMZN, AMD, and SHOP were also reduced.
Stueland Katherine (CHIEF EXECUTIVE OFFICER) sold 3,692 shares of GeneDx Holdings Corp. (WGS) at $84.22 ($0.31M total) on 2026-09-09.
Feeley Kevin (CHIEF FINANCIAL OFFICER) sold 1,285 shares of GeneDx Holdings Corp. (WGS) at $84.22 ($0.11M total) on 2026-09-09.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning WGS (GeneDx Holdings Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent WGS coverage spans market movers, insider activity and technology.
In the last 30 days, WGS insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($450K). The most active reporter was Feeley Kevin, CHIEF FINANCIAL OFFICER, with 2 filings.
Minor effect on WGS.
The insider sale modestly reduces insider ownership and may signal limited confidence.
The insider sale may signal personal confidence level but the amount is modest relative to total holdings.
The launch may increase test volumes and revenue growth, but reimbursement risk remains.
The launch is a product-access expansion that could support volume growth, but the article flags reimbursement pressure and execution risk.
AlphAI scores every news story that mentions WGS with an AI model for sentiment and relevance, and aggregates insider trades from GeneDx Holdings Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ARK Invest, led by Cathie Wood, sold shares in multiple crypto-linked holdings, including ARKB, COIN, CRCL, and BMNR. The firm trimmed over 1.5% of its Bitcoin ETF (ARKB) positions. Bitcoin's price fell below $77,000, and retail sentiment remained bearish. Other tech stocks like AMZN, AMD, and SHOP were also reduced.
2 min readStueland Katherine (CHIEF EXECUTIVE OFFICER) sold 3,692 shares of GeneDx Holdings Corp. (WGS) at $84.22 ($0.31M total) on 2026-09-09.
1 min readFeeley Kevin (CHIEF FINANCIAL OFFICER) sold 1,285 shares of GeneDx Holdings Corp. (WGS) at $84.22 ($0.11M total) on 2026-09-09.
1 min readGeneDx (WGS) launched a direct-to-family exome testing platform in August 2026, allowing families to initiate clinician-guided testing online. This aligns with updated AAP guidelines and targets underserved pediatric patients. The company projects $475M-$490M revenue for 2026 and $771.4M revenue by 2029, with analysts offering varied outlooks on growth and reimbursement risks.
3 min readSimply Wall St reports GeneDx Holdings (WGS) launched an online exome testing pathway on GeneDx.com for U.S. families, enabling clinician-guided tests for children with developmental delay, intellectual disability, or epilepsy. The article cites 30-day return of 18.05% and 90-day return of 91.61%, and discusses valuation versus analyst fair value ($77) and a DCF estimate ($236.93).
7 min readGeneDx reported Q2 2026 revenue of $114.4 million, up 11% year over year, with exome and genome revenue of $100.3 million (+17%). Adjusted net income was $0.4 million and adjusted diluted EPS $0.01. Q3 revenue guidance is $122 million to $124 million, and full-year 2026 revenue guidance is $475 million to $490 million.
6 min readInvesting.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.
6 min readGeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of 32% year-over-year • Reported adjusted gross margin (1) of
6 min readGeneDx Holdings (formerly Sema4, NASDAQ: WGS) and former officers filed responses in a federal securities class action over alleged overstated capabilities of Centrellis, an AI-molecular and phenotypic data system. The parties settled for about $4.8M to resolve claims of fraud tied to a 2022 GeneDx acquisition valued near $623M. Court filings were submitted July 24, 2026.
5 min readInvesting.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
5 min read
